Avadel Pharmaceuticals

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
Wednesday, May 8, 2024
FDA, Shanda, International, EDS, Food, Idiopathic hypersomnia, Webcast, Avadel Pharmaceuticals, Patient, Caregiver, Narcolepsy, Cataplexy, Marketing, Food and Drug Administration, Nursing

DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the quarter ended March 31, 2024.

Key Points: 
  • ET --
    DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the quarter ended March 31, 2024.
  • Recognized $27.2 million in net product revenue and gross profit of $25.7 million for the quarter ended March 31, 2024.
  • R&D expenses were $3.1 million in the quarter ended March 31, 2024, compared to $3.8 million for the same period in 2023.
  • SG&A expenses were $48.6 million in the quarter ended March 31, 2024, compared to $24.5 million for the same period in 2023.

Particle Dynamics Appoints New CFO as it Advances its Strategic Growth Plans

Retrieved on: 
Tuesday, April 23, 2024
Health Technology, Pharmaceutical, Health, Sigma-Aldrich, Microsoft Dynamics 365, Merck Group, Particle, OSD, Knowledge, Avadel Pharmaceuticals, Growth, Strategic planning, Management

Mike's appointment marks a significant milestone for Particle Dynamics, underscoring the company’s commitment to delivering enhanced value to clients and stakeholders.

Key Points: 
  • Mike's appointment marks a significant milestone for Particle Dynamics, underscoring the company’s commitment to delivering enhanced value to clients and stakeholders.
  • His proven track record in financial leadership and strategic planning will be instrumental in driving Particle Dynamics’ continued growth and success in the pharmaceutical and healthcare industries.
  • Nicolas Fortin, CEO of Particle Dynamics, said: “Mike’s extensive experience and financial leadership make him the ideal candidate to lead our finance team during this exciting period of growth and expansion.
  • I am confident Mike’s strategic vision will be invaluable as we continue to strengthen our position as a global leader in particle processing and delivery technologies."

Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, March 4, 2024
Idiopathic hypersomnia, Caregiver, Narcolepsy, Marketing, FDA, Food, System, Shanda, Cataplexy, UnitedHealth Group, Food and Drug Administration, Webcast, EDS, Patient, PBM, Avadel Pharmaceuticals, Trial of the century, Nursing

-- Management to host a conference call today at 7:30 a.m. ET --

Key Points: 
  • ET --
    DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the fourth quarter ended December 31, 2023.
  • “We are carrying significant momentum into 2024 following the successful launch of LUMRYZ and are pleased with the strong early launch results we have seen.
  • Recognized $19.5 million and $28.0 million in net product revenue for the quarter and year ended December 31, 2023, respectively.
  • Net product revenue consists of LUMRYZ product sales, which was launched in the U.S. on June 5, 2023.

Global Narcolepsy Drugs Market Research Report 2024: Pipeline Analysis, Key Company Profiles and Recent Developments 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 30, 2024
General Health, Pharmaceutical, Health, Narcolepsy, Jazz Pharmaceuticals, CIII, FDA, Central nervous system, Somnolence, Consciousness, Quality of life, DSM-IV codes, Mazindol, Takeda Pharmaceutical Company, Tobacco, Organization, Cataplexy, EDS, Prevalence, American Academy, CNS, Selective serotonin reuptake inhibitor, Growth, Patient, Diagnosis, Marketing, Disease, U.S. FDA, NINDS, Research, Therapy, Teva Pharmaceuticals, Investment, Avadel Pharmaceuticals, European Medicines Agency, Pharmaceutical industry

The "Global Narcolepsy Drugs Market (By Therapeutic Type, Disease Type, End User, Regional Analysis), Pipeline Analysis, Key Company Profiles and Recent Developments - Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Narcolepsy Drugs Market (By Therapeutic Type, Disease Type, End User, Regional Analysis), Pipeline Analysis, Key Company Profiles and Recent Developments - Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global narcolepsy drugs market has witnessed significant growth in recent years owing to the rising prevalence of narcolepsy and increased awareness about the condition.
  • Latin America and Middle East & Africa are competing closely to grab the maximum share of the global narcolepsy drugs market.
  • Global Narcolepsy Drugs Market - Key Company Profiles, Recent Developments, Financial Insights

Avadel Pharmaceuticals Announces Strong LUMRYZ Launch Performance and Provides Preliminary Fourth Quarter and Full Year 2023 Financial Highlights

Retrieved on: 
Monday, January 8, 2024
Shanda, CVS, Caregiver, GPO, FDA, Avadel Pharmaceuticals, Bank statement, System, Growth, Patient, Narcolepsy, PBM, Nursing

DUBLIN, Ireland, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a business update including preliminary estimates of fourth quarter and full year net revenue and cash, cash equivalents and marketable securities.

Key Points: 
  • “2023 was transformational for Avadel defined by significant growth and continued execution of milestones critical to Avadel’s success, beginning with the FDA approval and receipt of Orphan Drug Exclusivity for LUMRYZ.
  • The LUMRYZ launch has thus far been marked by robust demand and overwhelmingly positive feedback from the narcolepsy community, health care providers and payers.
  • Launch Progress Through December 31, 2023:
    Greater than 1,900 patients enrolled in Avadel’s RYZUP patient support services:
    More than 1,000 patients initiated therapy.
  • Approximately $19 million and $28 million of net product revenue, respectively, estimated for the quarter and year ended December 31, 2023.

Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 8, 2023
FDA, Policy, Narcolepsy, Food, Cataplexy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Poster, EDS, Caregiver, Avadel Pharmaceuticals, Marketing, CVS, NDA, Patient, Shanda, Video game, Nursing, Pharmaceutical industry, Cryptocurrency

-- Management to host a conference call today at 8:30 a.m. ET --

Key Points: 
  • ET --
    DUBLIN, Ireland, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the third quarter ended September 30, 2023.
  • R&D expenses were $2.8 million in the quarter ended September 30, 2023, compared to $2.9 million for the same period in 2022.
  • SG&A expenses were $39.2 million in the quarter ended September 30, 2023, compared to $14.1 million for the same period in 2022.
  • The Company drew the first $30.0 million tranche from a $75.0 million royalty financing arrangement on August 1, 2023.

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) at World Sleep 2023

Retrieved on: 
Friday, October 20, 2023
FDA, Headache, Narcolepsy, Incidence, NT2, Food, Health, Vomiting, Dizziness, Epworth Sleepiness Scale, Cataplexy, Nausea, Poster, Senior, EDS, Disease, Enuresis, Avadel Pharmaceuticals, World Sleep Day, Sodium oxybate, Doctor of Pharmacy, Body mass index, Sleep, CIII, Mitigation, Patient, Central nervous system, Pharmaceutical industry, Dietary supplement, NT1

DUBLIN, Ireland, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new and encore data supporting the clinical profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) and patient preference for a once-nightly oxybate in 15 poster presentations and two oral presentations, at World Sleep 2023, being held from October 20-25, 2023 in Rio de Janeiro, Brazil. LUMRYZ (previously known as FT218), is a U.S. Food and Drug Administration (FDA) approved extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.

Key Points: 
  • “We are excited to be at this year’s World Sleep meeting with another robust display of data that supports both the established clinical benefit of LUMRYZ,” said Jennifer Gudeman, PharmD, Senior Vice President, Medical and Clinical Affairs of Avadel.
  • “Quality sleep is a foundational pillar of health for people with narcolepsy, yet ~65% of patients with narcolepsy experience poor, fragmented sleep in addition to their daytime symptoms.
  • LUMRYZ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy called the LUMRYZ REMS.
  • Most common adverse reactions (incidence > 5% and greater than placebo) reported for all doses of LUMRYZ combined were nausea, dizziness, enuresis, headache, and vomiting.

Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023
Sodium oxybate, Cataplexy, NT2, Pharmacy, EDS, Narcolepsy, Marketing, Anxiety, Sleep, Sleep Research Society, American depositary receipt, NDA, Prescription, American Academy, U.S. FDA, Avadel Pharmaceuticals, American Academy of Sleep Medicine, Patient, NT1, ESI, Somnolence, Growth, FDA, Health, Pharmaceutical industry, Nursing, Fine chemical

DUBLIN, Ireland, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the second quarter ended June 30, 2023.

Key Points: 
  • ET --
    DUBLIN, Ireland, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the second quarter ended June 30, 2023.
  • Recognized $1.5 million in net product revenues for the second quarter 2023.
  • R&D expenses were $4.2 million in the quarter ended June 30, 2023, compared to $4.5 million for the same period in 2022.
  • SG&A expenses were $46.8 million in the quarter ended June 30, 2023, compared to $21.8 million for the same period in 2022.

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, August 3, 2023
Employment, Avadel Pharmaceuticals, Compensated emancipation, Pharmaceutical industry

DUBLIN, Ireland, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to three (3) new employees to purchase an aggregate of 26,000 ordinary shares under Avadel’s 2021 Inducement Plan.

Key Points: 
  • DUBLIN, Ireland, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to three (3) new employees to purchase an aggregate of 26,000 ordinary shares under Avadel’s 2021 Inducement Plan.
  • The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of the grant date and 25% on each anniversary thereafter.
  • The options are subject to the terms and conditions of Avadel’s 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants.

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, July 20, 2023
Employment, Avadel Pharmaceuticals, Compensated emancipation, Pharmaceutical industry

DUBLIN, Ireland, July 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to three (3) new employees to purchase an aggregate of 20,000 ordinary shares under Avadel’s 2021 Inducement Plan.

Key Points: 
  • DUBLIN, Ireland, July 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to three (3) new employees to purchase an aggregate of 20,000 ordinary shares under Avadel’s 2021 Inducement Plan.
  • The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of the grant date and 25% on each anniversary thereafter.
  • The options are subject to the terms and conditions of Avadel’s 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants.